

Ke-Nan Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1086626/publications.pdf>

Version: 2024-02-01

29
papers

1,416
citations

430754

18
h-index

526166

27
g-index

31
all docs

31
docs citations

31
times ranked

1342
citing authors

#	ARTICLE	IF	CITATIONS
1	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 1-12.	3.0	439
2	m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. <i>Aging</i> , 2019, 11, 1204-1225.	1.4	209
3	YTHDF2 facilitates UBXL1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF- κ B and promote the malignant progression of glioma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 109.	6.9	92
4	METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF- κ B to promote the malignant progression of IDH-wildtype glioma. <i>Cancer Letters</i> , 2021, 511, 36-46.	3.2	86
5	ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme. <i>Disease Markers</i> , 2019, 2019, 1-12.	0.6	66
6	Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. <i>Carcinogenesis</i> , 2019, 40, 1229-1239.	1.3	60
7	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 314-322.	1.9	42
8	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. <i>Modern Pathology</i> , 2019, 32, 4-15.	2.9	41
9	A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 439-447.	1.2	36
10	Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. <i>Cancer Cell International</i> , 2018, 18, 107.	1.8	33
11	Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 271-282.	1.4	31
12	Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. <i>Cancer Cell International</i> , 2019, 19, 155.	1.8	27
13	Identification of an ATP metabolism-related signature associated with prognosis and immune microenvironment in gliomas. <i>Cancer Science</i> , 2020, 111, 2325-2335.	1.7	27
14	Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10263-10273.	1.0	25
15	RGS16 promotes glioma progression and serves as a prognostic factor. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 791-803.	1.9	24
16	A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. <i>Frontiers in Genetics</i> , 2019, 10, 910.	1.1	22
17	Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 965-975.	1.9	21
18	Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. <i>Oncologist</i> , 2021, 26, e1460-e1469.	1.9	21

#	ARTICLE	IF	CITATIONS
19	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. JCI Insight, 2019, 5, .	2.3	20
20	ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2Q607R. Cancer Cell International, 2018, 18, 196.	1.8	19
21	SAMD9 Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma. Frontiers in Immunology, 2021, 12, 659659.	2.2	16
22	Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. Journal of Neurosurgery, 2022, 136, 67-75.	0.9	15
23	Molecular subtype impacts surgical resection in low-grade gliomas: A Chinese Glioma Genome Atlas database analysis. Cancer Letters, 2021, 522, 14-21.	3.2	10
24	Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas. Frontiers in Cell and Developmental Biology, 2020, 8, 580464.	1.8	8
25	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies (Review). Biomedical Reports, 2018, 10, 3-9.	0.9	7
26	New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis. Frontiers in Neurology, 2021, 12, 682535.	1.1	3
27	Hypoxia induced LBH overexpression accelerates malignant progression in glioma. EBioMedicine, 2019, 49, 4-5.	2.7	1
28	<i>LRRFIP1</i> , an epigenetically regulated gene, is a prognostic biomarker and predicts malignant phenotypes of glioma. CNS Neuroscience and Therapeutics, 2022, 28, 873-883.	1.9	1
29	Prognostic Pathways Guide Drug Indications in Pan-Cancers. Frontiers in Oncology, 2022, 12, 849552.	1.3	0